CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 200 target
Drug / intervention
Isoniazid +1 moredrug
Likely dose
Isoniazid 5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00293228
NCT00293228Phase 4Completed
CompareCT.gov

Drugs for Treatment of Latent Tuberculosis Infection Objective 4: Identify Biomarkers for Clinical Trials of Drugs Active Against Latent TB

Instituto Nacional de Salud Publica, Mexico·interventional·Posted Feb 17, 2006·Updated May 26, 2010

In Brief

A Phase 4 clinical trial evaluating Isoniazid and isoniazid for Tuberculosis. Completed, enrolled 200 participants across 1 site.

Detailed Summary

The purpose of this study is to study the effect that treatment of dormant tuberculosis infection has on the immunological system. We expect to observe an impact over the production of cytokines by peripheral white blood cells which may be useful to know if treatment has been effective.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTuberculosis
CountriesMexico
CollaboratorsBill and Melinda Gates Foundation, Wellcome Trust

Timeline

Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 17, 2006
Enrollment StartFeb 1, 2007
Primary CompletionMar 1, 2008
Study CompletionJun 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 20.4 years ago

Interventions

Isoniaziddrug

Isoniazid (5mg per kg up to 300 mg daily for 6 months)

isoniaziddrug

isoniazid (5mg per kg up to 300 mg daily for 6 months